A 24% dementia gap, and 1.7% uptake: the shingles number nursing homes will be asked about

The effect size needs no modelling to see: the ratio of the two arms' rates is 0.764, a 23.6% relative reduction that lands on the reported figure to within rounding ^[4]. In absolute terms the gap is 5.8 percentage points, which inverts to 17.2 residents vaccinated for each dementia diagnosis not recorded ^[3]. Applied to the 501,083 people in the cohort who went unvaccinated ^[2], that spread implies on the order of 29,000 dementia diagnoses across four years ^[5]. That figure is worth computing only as a measure of what rides on the causal question, and nothing in a claims database settles it.

The other number in the paper is 8,843 ^[4]. Against 509,926 vaccine-eligible residents in more than 5,500 facilities ^[3], that is 1.7% ^[1], or fewer than two vaccinated residents per facility across five years of admissions ^[6]. The exposed arm is therefore not a population that was offered a vaccine; it is the handful of people somebody chose to vaccinate in a setting where nobody was doing it systematically. The authors report the vaccinated were slightly younger and healthier and that adjusting for those differences did not make the association disappear [c8b]. The direction of what remains is not mysterious, though. Whatever a clinician saw in that 1.7% that made a shingles dose worth ordering points the same way as lower dementia risk. And the endpoint is a recorded diagnosis, not a pathology finding; who gets worked up for cognitive decline in a skilled nursing facility is not random either.

Which leaves the trials the authors ask for ^[9]. Target trial emulation exists precisely because the randomized version is impractical ^[10], and Shingrix arrived in 2017 and remains the only shingles vaccine on the market ^[11], so a control arm means declining a recommended vaccine to vulnerable older adults and then waiting four years to count diagnoses. Nobody is handing a medical director a cleaner answer this decade. This estimate, with its 1.7% exposure and its healthier vaccinees, is the evidence that will be cited in the meantime, and the earlier work it echoes used the older vaccine ^[14].

The usable reading is narrower than the headline. Hayes describes admission to a skilled nursing facility as a clear clinical point of care in a population not up to date on shingles vaccination ^[13], and the case for a standing order there rests on shingles itself, which she notes the vaccines do prevent ^[15]. The dementia association does not have to be causal for 1.7% to look like a defect rather than a baseline.